[1]
|
Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management
Journal of Pharmaceutical Analysis,
2024
DOI:10.1016/j.jpha.2023.09.009
|
|
|
[2]
|
Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction
Journal of Pharmaceutical and Biomedical Analysis,
2023
DOI:10.1016/j.jpba.2023.115281
|
|
|
[3]
|
Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction
Journal of Pharmaceutical and Biomedical Analysis,
2023
DOI:10.1016/j.jpba.2023.115281
|
|
|
[4]
|
Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
Antimicrobial Agents and Chemotherapy,
2022
DOI:10.1128/aac.02144-21
|
|
|
[5]
|
Prediction of Human Pharmacokinetic Profiles of the Antituberculosis Drug Delamanid from Nonclinical Data: Potential Therapeutic Value against Extrapulmonary Tuberculosis
Antimicrobial Agents and Chemotherapy,
2021
DOI:10.1128/AAC.02571-20
|
|
|
[6]
|
Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples
Journal of Chromatography B,
2021
DOI:10.1016/j.jchromb.2020.122467
|
|
|
[7]
|
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
Antimicrobial Agents and Chemotherapy,
2020
DOI:10.1128/AAC.01207-20
|
|
|
[8]
|
Development and validation of LC–MS/MS method for determination of DNDI-VL-2098 in mouse, rat, dog and hamster blood
Bioanalysis,
2019
DOI:10.4155/bio-2019-0128
|
|
|
[9]
|
Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis
Biopharmaceutics & Drug Disposition,
2017
DOI:10.1002/bdd.2064
|
|
|
[10]
|
Absorption, distribution and excretion of the anti‐tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis
Biopharmaceutics & Drug Disposition,
2017
DOI:10.1002/bdd.2064
|
|
|
[11]
|
Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC–MS/MS
Journal of Chromatography B,
2015
DOI:10.1016/j.jchromb.2015.07.058
|
|
|